AstraZeneca has successfully completed its acquisition of US-based clinical-stage biopharmaceutical company, Icosavax. Through this acquisition, AstraZeneca will be able to expand its expertise in respiratory syncytial virus (RSV) thanks to Icosavax’s lead investigational vaccine candidate, IVX-A12—a combination protein virus-like particle (VLP) platform vaccine that targets RSV and human metapneumovirus (hMPV). Source: Biopharm International 21/2/2024